Does the EU Pharmaceutical Sector Inquiry Provide Proof of the Need for a Centralised Patent Court?
This article was originally published in SRA
Executive Summary
Generic drug companies hoping to have cases heard against “weak patents” in the UK courts may be well advised to steer clear of Lord Justice Robin Jacob. A judge in the Court of Appeal, and one of the UK’s most experienced patent judges, Lord Justice Jacob recently suggested that the European Commission’s inquiry into competition in the pharmaceutical sector was simply “a waste of time”.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.